Novo Nordisk’s Tresiba branding will be showcased on Charlie Kimball’s No. 83 Novo Nordisk Chip Ganassi Racing Chevrolet for the 2016 Verizon IndyCar Series season. There was a soft launch of the new livery at St. Petersburg, with the full colors and signage now on board from Phoenix this weekend.
The team’s full release is below:
Chip Ganassi Racing Teams, INDYCAR driver Charlie Kimball and Novo Nordisk, a world leader in diabetes care, w ill unveil a new livery for the No. 83 entry fielded by Novo Nordisk Chip Ganassi Racing when the car takes the track at the Phoenix Grand Prix. The car features a new black and green color scheme and carries the logo of Tresiba® (insulin degludec injection), Novo Nordisk’s once-daily, long-acting basal insulin. Tresiba was approved by the U.S. Food and Drug Administration (FDA) in September 2015.
The 2016 race season marks the eighth consecutive year of partnership between Novo Nordisk and Kimball. Since his type 1 diabetes diagnosis, Kimball has been a passionate diabetes advocate. He is the face of Novo Nordisk’s award-winning Race with Insulin campaign, which aims to raise awareness and educate the public about diabetes management.
“The new look of this car represents something very personal to me. Just as there have been advancements in racing, there have been advancements in the management of diabetes. The new look of my 2016 car represents another strong link between this program and the diabetes community,” said Kimball. “I am excited about the new design, not only because of the new look, but also because it represents the next phase in my effort to educate others.”
“We love the new look of Charlie’s car and are thrilled to continue our partnership with Charlie and Chip Ganassi Racing. It has been rewarding to see Charlie inspire and educate others affected by diabetes,” said Camille Lee, senior vice president, Diabetes & Obesity Marketing, Novo Nordisk Inc. “We are looking forward to a great season with Charlie and the No. 83 Tresiba Chevrolet, and are extremely excited about the future of the Race with Insulin campaign.”
Continue to follow Charlie’s journey and his work with Novo Nordisk at RaceWithInsulin.com, learn more about Tresiba (insulin degludec injection 200 Units/mL) at Tresiba.com, or follow Charlie on Twitter at @racewithinsulin.